Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-1295
Leukemia Therapeutics Market is estimated to value over CAGR of over 5.8% during the forecast period 2022 to 2028. The global leukemia therapeutics market growth is steered by factors, for instance, a plethora of available treatment alternatives for treating chronic myeloid leukemia and high prevalence rate of chronic myeloid leukemia are substantially assisting the market growth. For example, in the United States, there were over 20,000 new cases of chronic myeloid leukemia in 2018. Additionally, the segment growth is guided by the ever-increasing ageing population and increasing research funds for cancer treatments and for developing innovative therapies. Increasing investments for innovative research and development activities in drug development and discovery, growing overall volume of biotechnology companies and is predicted to spur the augmentation of the market. Likewise, the introduction of advanced therapeutics with fewer side effects and more efficiency, pipeline products awaiting approvals and metabolic inhibitors are projected to steer the market growth throughout the forecast timeframe. Rising awareness amongst patients pertaining to recent advancements in technology and advantages, for instance, safety, tolerability and efficacy are the factors projected to boost the market growth. Current research in molecular diagnosis is anticipated to dominate with the accessibility of various leukemia treatments and is projected to expand the global leukemia therapeutics market size. Due to the soaring insistence for targeted drugs, they are likely to subjugate the global market over the forecast timeframe. The targeted drugs are prominently used due to their higher success rate and efficacy in comparison with chemotherapy and fewer side effects. These factors are the reason for the rise in their sales over the past few years. The Asia Pacific region is anticipated to rapidly proliferate owing to numerous incomplete needs in the developing markets, for instance, India, Japan and China and growing investments in the expenditure assigned to the research and development by major biotechnology companies. A healthcare infrastructure that is rapidly growing, high penetration rates of the market and increasing levels of awareness are the major factors contributing to the augmentation of the market in the region. Key market players are: Novartis AG, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Sanofi, Pfizer, Amgen, Gilead Sciences, Takeda, Celgene. Leukemia Therapeutics Market Segmentation: By Type of Leukemia Chronic Myeloid Leukemia Chronic Lymphocytic Leukemia Acute Lymphocytic Leukemia Acute Myeloid Leukemia By Treatment Type Targeted Drugs & Immunotherapy Chemotherapy By Molecule Type Small Molecules Biologics By Mode of Administration Oral Mode Injectable Mode By Gender Males Females By Region North America Latin America Europe Asia-Pacific Middle East and Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global leukemia therapeutics market by type of leukemia, by treatment type, by molecule type, by mode of administration, by gender and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization services offered are free of charge with purchase of any license of the report. You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The global leukemia therapeutics market growth is steered by factors, for instance, a plethora of available treatment alternatives for treating chronic myeloid leukemia and high prevalence rate of chronic myeloid leukemia are substantially assisting the market growth. For example, in the United States, there were over 20,000 new cases of chronic myeloid leukemia in 2018. Additionally, the segment growth is guided by the ever-increasing ageing population and increasing research funds for cancer treatments and for developing innovative therapies.
Increasing investments for innovative research and development activities in drug development and discovery, growing overall volume of biotechnology companies and is predicted to spur the augmentation of the market. Likewise, the introduction of advanced therapeutics with fewer side effects and more efficiency, pipeline products awaiting approvals and metabolic inhibitors are projected to steer the market growth throughout the forecast timeframe. Rising awareness amongst patients pertaining to recent advancements in technology and advantages, for instance, safety, tolerability and efficacy are the factors projected to boost the market growth. Current research in molecular diagnosis is anticipated to dominate with the accessibility of various leukemia treatments and is projected to expand the global leukemia therapeutics market size.
Due to the soaring insistence for targeted drugs, they are likely to subjugate the global market over the forecast timeframe. The targeted drugs are prominently used due to their higher success rate and efficacy in comparison with chemotherapy and fewer side effects. These factors are the reason for the rise in their sales over the past few years.
The Asia Pacific region is anticipated to rapidly proliferate owing to numerous incomplete needs in the developing markets, for instance, India, Japan and China and growing investments in the expenditure assigned to the research and development by major biotechnology companies. A healthcare infrastructure that is rapidly growing, high penetration rates of the market and increasing levels of awareness are the major factors contributing to the augmentation of the market in the region.
Key market players are: Novartis AG, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Sanofi, Pfizer, Amgen, Gilead Sciences, Takeda, Celgene.
Leukemia Therapeutics Market Segmentation:
By Type of Leukemia
By Treatment Type
By Molecule Type
By Mode of Administration
By Gender
By Region
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Leukemia Therapeutics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Leukemia Therapeutics Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Leukemia Therapeutics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Leukemia Therapeutics Market, By Type of Leukemia Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Chronic Myeloid Leukemia 7.2. Chronic Lymphocytic Leukemia 7.3. Acute Lymphocytic Leukemia 7.4. Acute Myeloid Leukemia 8. Global Leukemia Therapeutics Market, By Treatment Type Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Targeted Drugs & Immunotherapy 8.2. Chemotherapy 9. Global Leukemia Therapeutics Market, By Molecule Type Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Small Molecules 9.2. Biologics 10. Global Leukemia Therapeutics Market, By Mode of Administration Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Oral Mode 10.2. Injectable Mode 11. Global Leukemia Therapeutics Market, By Gender Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Males 11.2. Females 12. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Switzerland 14.2.9. Rest of Western Europe 15. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. Singapore 15.2.4. India 15.2.5. Australia and New Zealand 15.2.6. ASEAN 15.2.7. South Korea 15.2.8. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 17.1. Novartis AG 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. AbbVie 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Bristol-Myers Squibb 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. F. Hoffmann-La Roche 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Sanofi 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Pfizer 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Amgen 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Gilead Sciences 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Takeda 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10. Celgene 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME key takeaway points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics